Amgen's Major Expansion in Ohio: A $900 Million Investment Creating 350 New Jobs
Amgen, the renowned biotechnology company, has revealed its plans for a substantial expansion of its manufacturing facility located in Ohio. This initiative involves a staggering investment of $900 million, which is set to create 350 new jobs, significantly contributing to the local economy and reinforcing Amgen's commitment to U.S. manufacturing. With this latest expansion, Amgen's total investment in Central Ohio will surpass $1.4 billion, a remarkable feat that underscores the company's dedication to enhancing its manufacturing capabilities within the region.
Founded in 1980, Amgen has long been recognized as a leader in the development and production of biopharmaceuticals, focusing on innovative therapies for various serious diseases. The recent expansion announcement was made by Robert A. Bradway, Amgen's Chairman and CEO, who emphasized the importance of Ohio's business landscape in the company's growth strategy. He stated, "Ohio offers a supportive business climate, a skilled workforce, and a strategic location, making it an ideal choice for this next phase of our investment."
Amgen first established a presence in Ohio in June 2021 when it invested in a state-of-the-art biomanufacturing facility in the Columbus Region, which initially resulted in the creation of 400 jobs. This latest expansion demonstrates the ongoing growth trajectory of the company in Ohio, showcasing the state as a prime hub for biotechnology development. Ohio Governor Mike DeWine expressed optimism regarding Amgen's deepened commitment, noting, "Ohio has built a strong foundation for economic development, which has led companies like Amgen to see Ohio as a premier destination for growth."
The significance of Amgen's investment extends beyond job creation. Since the passage of the Tax Cuts and Jobs Act of 2017, Amgen has invested nearly $5 billion in direct capital expenditures within the United States. This extensive investment has resulted in an estimated additional economic output of approximately $12 billion for the U.S. economy, contributing to the overall improvement of local communities and infrastructure.
Moreover, the Ohio expansion not only reinforces Amgen's position in the U.S. market but also complements its overarching strategy to enhance a global biomanufacturing network. Coupled with a recent announcement regarding a separate $1 billion investment to build a second manufacturing plant in Holly Springs, North Carolina, it is evident that Amgen is heavily focused on innovating and fortifying its production capabilities across the nation.
Amgen's endeavors are pivotal in the biotechnology landscape, as the company sets about identifying and developing innovative therapies that address urgent medical needs. With over four decades of experience, Amgen maintains a robust pipeline of medicines targeted at treating cancer, heart disease, osteoporosis, inflammatory conditions, and rare diseases. Recognized as one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, Amgen continues to thrive within the biotechnology sector.
As part of the Dow Jones Industrial Average and the Nasdaq-100 Index, Amgen exemplifies not only growth and innovation but also a commitment to positively impacting patient lives through advanced medical treatments. The company’s strategic decision to expand in Ohio is more than just a financial investment; it represents a commitment to local communities, job creation, and continued support for the healthcare systems that rely on their biopharmaceutical products.
For ongoing updates and insights into Amgen's revolutionary advancements, visit their official website or follow them on various social media platforms, including LinkedIn and Instagram. With developments like this expansion, Amgen is set to play a significant role in not only the biotechnology industry but also in the economic growth of Ohio and beyond.
Founded in 1980, Amgen has long been recognized as a leader in the development and production of biopharmaceuticals, focusing on innovative therapies for various serious diseases. The recent expansion announcement was made by Robert A. Bradway, Amgen's Chairman and CEO, who emphasized the importance of Ohio's business landscape in the company's growth strategy. He stated, "Ohio offers a supportive business climate, a skilled workforce, and a strategic location, making it an ideal choice for this next phase of our investment."
Amgen first established a presence in Ohio in June 2021 when it invested in a state-of-the-art biomanufacturing facility in the Columbus Region, which initially resulted in the creation of 400 jobs. This latest expansion demonstrates the ongoing growth trajectory of the company in Ohio, showcasing the state as a prime hub for biotechnology development. Ohio Governor Mike DeWine expressed optimism regarding Amgen's deepened commitment, noting, "Ohio has built a strong foundation for economic development, which has led companies like Amgen to see Ohio as a premier destination for growth."
The significance of Amgen's investment extends beyond job creation. Since the passage of the Tax Cuts and Jobs Act of 2017, Amgen has invested nearly $5 billion in direct capital expenditures within the United States. This extensive investment has resulted in an estimated additional economic output of approximately $12 billion for the U.S. economy, contributing to the overall improvement of local communities and infrastructure.
Moreover, the Ohio expansion not only reinforces Amgen's position in the U.S. market but also complements its overarching strategy to enhance a global biomanufacturing network. Coupled with a recent announcement regarding a separate $1 billion investment to build a second manufacturing plant in Holly Springs, North Carolina, it is evident that Amgen is heavily focused on innovating and fortifying its production capabilities across the nation.
Amgen's endeavors are pivotal in the biotechnology landscape, as the company sets about identifying and developing innovative therapies that address urgent medical needs. With over four decades of experience, Amgen maintains a robust pipeline of medicines targeted at treating cancer, heart disease, osteoporosis, inflammatory conditions, and rare diseases. Recognized as one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, Amgen continues to thrive within the biotechnology sector.
As part of the Dow Jones Industrial Average and the Nasdaq-100 Index, Amgen exemplifies not only growth and innovation but also a commitment to positively impacting patient lives through advanced medical treatments. The company’s strategic decision to expand in Ohio is more than just a financial investment; it represents a commitment to local communities, job creation, and continued support for the healthcare systems that rely on their biopharmaceutical products.
For ongoing updates and insights into Amgen's revolutionary advancements, visit their official website or follow them on various social media platforms, including LinkedIn and Instagram. With developments like this expansion, Amgen is set to play a significant role in not only the biotechnology industry but also in the economic growth of Ohio and beyond.
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.